Library of the School of Health Sciences
ΠΜΣ Ογκολογία Θώρακα: Σύγχρονη Κλινικο-Εργαστηριακή Προσέγγιση και Έρευνα

2024-03-21

2024

Nikolakopoulou Asimina

Πέτρος Μπακάκος, Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ, Επιβλέπων
Κωνσταντίνος Ν. Συρίγος, Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ
Γρηγόριος Στρατάκος, Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ

Ενδοκρινολογικές διαταραχές σε ανοσοθεραπεία καρκίνου πνεύμονα. Η εμπειρία ενός κέντρου.

Greek

Εndocrine side effects due to immunotherapy in patients with lung cancer. The experience of a medical clinic.

Immune checkpoint inhibitors are considered as relatively recent treatment strategy for lung cancer. However, due of their association with autoimmunity, immune checkpoint inhibitors have been associated with a variety of side effects involving many organs, including the endocrine system (3-23%). Therefore, the present study aimed to record the side effects of immunotherapy with PD-1 and PD-L1 inhibitors in patients with stage IV lung cancer. The medical data of 72 patients with lung cancer treated with PD-1 and PD-L1 inhibitors in the 2nd Pulmonology Clinic of the General Hospital of Thoracic Diseases of Athens, «Sotiria» were collected between 01.01.2021-31.12.2021. A total of 19/72 (26.4%) showed immunotherapy-related toxicity. More specifically, 9/19 (47.4%), 8/19 (42.1%) and 2/19 (10.5%) patients treated with Pembrolizumab, Nivolumab and Atezolizumab, respectively, experienced side effects related to the endocrine system. Of these patients, 12 (16,7%) had hypothyroidism and 7 (9,7%) hyperthyroidism. Only 4 of 19 patients (21%) had to receive any type of treatment for the side effects and no patient discontinued their treatment. Regarding patient survival, one patient from the toxicity group died of COVID-19 complications, while among the non-toxicity patients 9 died, 2 from COVID-19 complications and 7 from lung cancer complications (1-year survival rate 83%). The results of the present study showed that one in four patients with lung cancer treated with immunotherapy are likely to develop endocrine side effects due to immunotherapy. Therefore, the development of a multidisciplinary approach to identify and promptly treat any adverse event is of great importance.

Health Sciences

Endocrine side effects, Immunotherapy, Lung cancer

No

0

Yes

208

138

File access is restricted only to the intranet of UoA.

https://pergamos.lib.uoa.gr/uoa/dl/object/3392527